

Xtep (1368 HK)

Excellent YTD performance among all brands

FY22 results and FY23E guidance were roughly inline but the YTD performance was impressive and solid. We still like Xtep due to its attractive PEG of 0.7x.

- FY22 results inline. Xtep's sales grew by 29% YoY to RMB 12.9bn while net profit rose by 1% YoY to RMB 922mn. The new brands (K&P, S&M) registered a loss of RMB 222mn, missing management est. of no more than RMB 150mn, mainly because of pandemic in 4Q22.
- Robust retail sales growth registered in YTD 2023. Management highlighted about mid-teens/ 20%+ retail sales growth for Xtep in Jan-Feb/Mar 2023. These figures are very encouraging and far better than Anta and Li Ning's. Once again, offline outperformed the online (except the still fast-growing live steaming e-commerce with better margins).
- Inventory already become healthier and should normalize by 3Q-4Q23E. Inventory to sales ratio also improved significantly, from over 5 months in 4Q22 to below 5 months in 1Q23E. Since the inventory from 3Q-4Q22 was still excessive, de-stocking process should last into 2H23E and hopefully be done before double-11. The need of deep retail discounts is now gone.
- A fair but still industry leading FY23E guidance. Xtep brand is now targeting a 20%+ retail sales growth, a mid-teen listed co sales growth and an even faster net profit growth in FY23E. Xtep kid is about to grow by 20%-30%. In fact, we are fairly confident for the Company to achieve this goal, considering: 1) excellent YTD performance and the low bases, 2) strong momentum from running segment, helped by the return of marathons in China, as well as many headlines about "record breaking" made by the athletes wearing Xtep shoes, 3) store revamps, 4) expansion into higher tier cities, etc.. On the other hand, management is also targeting a 41-42% GP margin and a similar to FY22E level NP margin for Xtep core brand.
- New brands are fast growing and hopefully will narrow down the losses. The JV (Saucony & Merrell) had a very rapid sales growth of 99% in FY22, and it will still grow fast, by 60%-70% in FY23E, thanks to reopening of sports events, e-commerce business and around 30-50 new stores. Breakeven is likely in FY23E. K-Swiss & Palladium sales grew by 44% in FY22 but generated a greater than expected loss. In FY23E, the Company is aiming for a 20%-30% sales growth, mainly due to expansion in China (about 30-40 net new stores) and a sluggish overseas growth, while the net loss should be less than RMB 150mn.
- Maintain BUY but raised TP to HK\$ 10.54, based on 21x FY23E P/E, about 1 s.d. above the 5 years average of 15x. We cut FY23E/24E net profit by 5%/5%, to factor in faster sales growth but a lower GP margin. It is trading at 17x FY23E P/E, not demanding at all.

Earnings Summary

| (YE 31 Dec) | FY21A | FY22A | FY23E | FY24E | FY25E |
|-------------------------------|---------------|----------|----------|---------|---------|
| Revenue (RMB mn) | 10,013 | 12,930 | 15,113 | 17,550 | 20,008 |
| YoY growth (%) | 22.5 | 29.1 | 16.9 | 16.1 | 14.0 |
| Operating profit (RMB mn) | 1,396 | 1,464 | 1,807 | 2,174 | 2,650 |
| Net profit (RMB mn) | 889.4 | 912.3 | 1,190.3 | 1,478.3 | 1,854.9 |
| EPS (Reported) (RMB) | 0.36 | 0.36 | 0.47 | 0.60 | 0.74 |
| YoY growth (%) | 72.1 | 0.6 | 32.6 | 26.5 | 23.4 |
| P/E (x) | 19.9 | 21.7 | 17.3 | 14.0 | 11.2 |
| P/B (x) | 2.3 | 2.5 | 2.3 | 2.1 | 2.0 |
| Yield (%) | 3.0 | 2.3 | 3.5 | 4.3 | 5.4 |
| ROE (%) | 11.9 | 11.3 | 13.7 | 15.9 | 18.5 |
| Net gearing (%) | Net cash | Net cash | Net cash | 4.5 | 8.8 |
| Source: Company data, Bloombe | rg, CMBIGM es | timates | | | |

BUY (Maintain)

Target Price HK\$10.54
(Previous TP HK\$10.44)
Up/Downside 21.3%
Current Price HK\$8.69

China Consumer Discretionary

Walter WOO (852) 3761 8776 walterwoo@cmbi.com.hk

Raphael TSE (852) 3900 0856 raphaeltse@cmbi.com.hk

raphaeltse@cmbi.com.hk Stock Data

 Mkt Cap (HK\$ mn)
 22,896.8

 Avg 3 mths t/o (HK\$ mn)
 9.3

 52w High/Low (HK\$)
 14.78/6.85

 Total Issued Shares (mn)
 2634.8

Source: FactSet

Shareholding StructureMr Ding Shui Po & Family49.0%JP Morgan Chase4.6%

Source: HKEx

Share Performance

| | Absolute | Relative |
|-------|----------|----------|
| 1-mth | -4.6% | -0.6% |
| 3-mth | 0.9% | 1.4% |
| 6-mth | -8.7% | -15.4% |

Source: FactSet

12-mth Price Performance



Source: FactSet



Earnings revision

Figure 1: Earnings revision

| | | New | | | Old | | | Diff (%) | |
|------------------------|--------|--------|--------|--------|--------|-------|---------|----------|-------|
| RMB mn | FY23E | FY24E | FY25E | FY23E | FY24E | FY25E | FY23E | FY24E | FY25E |
| Revenue | 15,113 | 17,550 | 20,008 | 14,395 | 16,447 | n/a | 5.0% | 6.7% | n/a |
| Gross profit | 6,224 | 7,273 | 8,345 | 6,093 | 7,032 | n/a | 2.2% | 3.4% | n/a |
| EBIT | 1,807 | 2,174 | 2,650 | 1,878 | 2,287 | n/a | -3.8% | -4.9% | n/a |
| Net profit att. | 1,181 | 1,461 | 1,832 | 1,237 | 1,545 | n/a | -4.5% | -5.4% | n/a |
| Diluted EPS (RMB) | 0.448 | 0.555 | 0.695 | 0.470 | 0.586 | n/a | -4.5% | -5.4% | n/a |
| Gross margin | 41.2% | 41.4% | 41.7% | 42.3% | 42.8% | n/a | -1.1ppt | -1.3ppt | n/a |
| EBIT margin | 12.0% | 12.4% | 13.2% | 13.0% | 13.9% | n/a | -1.1ppt | -1.5ppt | n/a |
| Net profit att. margin | 7.8% | 8.3% | 9.2% | 8.6% | 9.4% | n/a | -0.8ppt | -1.1ppt | n/a |

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

| | | CMBIGM | | | Consensus | | | Diff (%) | |
|------------------------|--------|--------|--------|--------|-----------|--------|---------|----------|---------|
| RMB mn | FY23E | FY24E | FY25E | FY23E | FY24E | FY25E | FY23E | FY24E | FY25E |
| Revenue | 15,113 | 17,550 | 20,008 | 14,886 | 17,840 | 20,575 | 1.5% | -1.6% | -2.8% |
| Gross profit | 6,224 | 7,273 | 8,345 | 6,194 | 7,490 | 8,612 | 0.5% | -2.9% | -3.1% |
| EBIT | 1,807 | 2,174 | 2,650 | 1,789 | 2,243 | 2,621 | 1.0% | -3.1% | 1.1% |
| Net profit att. | 1,181 | 1,461 | 1,832 | 1,193 | 1,495 | 1,758 | -1.0% | -2.3% | 4.2% |
| Diluted EPS (RMB) | 0.448 | 0.555 | 0.695 | 0.455 | 0.573 | 0.668 | -1.6% | -3.2% | 4.2% |
| Gross margin | 41.2% | 41.4% | 41.7% | 41.6% | 42.0% | 41.9% | -0.4ppt | -0.5ppt | -0.1ppt |
| EBIT margin | 12.0% | 12.4% | 13.2% | 12.0% | 12.6% | 12.7% | -0.1ppt | -0.2ppt | 0.5ppt |
| Net profit att. margin | 7.8% | 8.3% | 9.2% | 8.0% | 8.4% | 8.5% | -0.2ppt | -0.1ppt | 0.6ppt |



Results Summary

Figure 3: Results summary - Half Year

| Half yearly (RMB mn) | 1H21 | 2H22 | 1H22E | 2H22 | 1H21 YoY | 2H21 YoY | 1H22 E YoY | 2H22 E YoY | 1H22E CMBI GM | Actual vs CMBIG M |
|------------------------------|--------|--------|--------|---------------|-------------|-------------|---------------|---------------|---------------------|----------------------------|
| Revenue | 4,135 | 5,878 | 5,684 | 7,247 | 12% | 31% | 37% | 23% | 6,973 | 4% |
| COGS | -2,406 | -3,430 | -3,297 | -4,342 | | | | | -4,190 | |
| Gross profit | 1,729 | 2,449 | 2,387 | 2,905 | 16% | 43% | 38% | 19% | 2,783 | 4% |
| GP margins | 41.8% | 41.7% | 42.0% | 40.1% | | | | | 39.9% | |
| Other income & gains | 211 | 88 | 237 | 79 | | | | | 54 | 47% |
| S & D expenses | -774 | -1,117 | -1,046 | -1,644 | 13% | 31% | 35% | 47% | -1,454 | 13% |
| S & D exp / sales | -18.7% | -19.0% | -18.4% | -22.7% | | | | | -20.9% | |
| Admin expenses | -483 | -707 | -656 | -798 | -6% | 31% | 36% | 13% | -870 | -8% |
| Admin exp / sales | -11.7% | -12.0% | -11.5% | -11.0% | | | | | -12.5% | |
| Other opex | 0 | 0 | 0 | 0 | | | | | 0 | |
| Operating profit (EBIT) | 684 | 713 | 922 | 543 | 37% | 71% | 35% | -24% | 513 | 6% |
| OP margins | 16.5% | 12.1% | 16.2% | 7.5% | | | | | 7.4% | |
| Other items | 0 | 0 | 0 | 0 | | | | | 0 | |
| Net finance income | -30 | -33 | -28 | -63 | | | | | -20 | 223% |
| Net finance income / sales | -0.7% | -0.6% | -0.5% | -0.9% | | | | | -0.3% | |
| Profit after financing costs | 653 | 680 | 893 | 480 | | | | | 493 | |
| Associated coms | -8 | -39 | -11 | -1 | | | | | -33 | |
| Jointly controlled coms | 0 | 0 | 0 | 0 | | | | | 0 | |
| Pre-tax profit | 646 | 641 | 882 | 479 | 54% | 87% | 37% | -25% | 460 | 4% |
| Tax | -224 | -173 | -293 | -155 | | | | | -136 | |
| Tax / sales | -5.4% | -3.0% | -5.2% | -2.1% | | | | | -2.0% | |
| Effective tax rate | -34.7% | -27.1% | -33.2% | -32.5% | | | | | -29.6% | |
| Minority interests | -5 | -14 | -1 | -8 | | | | | -12 | |
| Net profit att. | 427 | 482 | 590 | 331 | 72% | 82% | 38% | -31% | 336 | -1% |
| NP margins | 10.3% | 8.2% | 10.4% | 4.6% | | | | | 4.8% | |
| Sales by segment | | | | | | | | | | |
| Mass market | 3,597 | 5,244 | 4,898 | 6,230 | 12% | 34% | 36% | 19% | 6,090 | 2% |
| Athleisure | 462 | 509 | 630 | 773 | 1% | -6% | 36% | 52% | 637 | 21% |
| Professional sports | 76 | 125 | 157 | 244 | 289% | 140% | 106% | 95% | 247 | -1% |
| Total | 4,135 | 5,878 | 5,684 | 7,247 | 12% | 31% | 37% | 23% | 6,973 | 4% |



Figure 4: Results summary - Full Year

| Full yearly (RMB mn) | FY21 | FY22 | FY23E | FY21 YoY | FY22 YoY | FY23E YoY | FY22E CMBIG M | Actual vs CMBIG M |
|------------------------------|--------|--------|--------|-------------|-------------|--------------|---------------------|----------------------------|
| Revenue | 10,013 | 12,930 | 15,113 | 23% | 29% | 17% | 12,657 | 2% |
| COGS | -5,835 | -7,639 | -8,888 | | | | -7,487 | |
| Gross profit | 4,178 | 5,292 | 6,224 | 31% | 27% | 18% | 5,170 | 2% |
| GP margins | 41.7% | 40.9% | 41.2% | | | | 40.8% | |
| Other income & gains | 299 | 317 | 332 | | | | 291 | 9% |
| S & D expenses | -1,891 | -2,690 | -3,021 | 23% | 42% | 12% | -2,500 | 8% |
| S & D exp / sales | -18.9% | -20.8% | -20.0% | | | | -19.8% | |
| Admin expenses | -1,189 | -1,454 | -1,759 | 13% | 22% | 21% | -1,526 | -5% |
| Admin exp / sales | -11.9% | -11.2% | -11.6% | | | | -12.1% | |
| Other opex | 0 | 0 | 0 | | | | 0 | |
| Operating profit (EBIT) | 1,396 | 1,464 | 1,777 | 52% | 5% | 21% | 1,435 | 2% |
| OP margins | 13.9% | 11.3% | 11.8% | | | | 11.3% | |
| Other items | -46 | -12 | -6 | | | | -44 | |
| Net finance income | -63 | -91 | -82 | | | | -48 | 91% |
| Net finance income / sales | -0.6% | -0.7% | -0.5% | | | | -0.4% | |
| Profit after financing costs | 1,287 | 1,361 | 1,689 | | | | 1,343 | |
| Associated coms | 0 | 0 | 0 | | | | 0 | |
| Jointly controlled coms | 0 | 0 | 0 | | | | 0 | |
| Pre-tax profit | 1,287 | 1,361 | 1,689 | 69% | 6% | 24% | 1,343 | 1% |
| Tax | -397 | -449 | -524 | | | | -430 | |
| Tax / sales | -4.0% | -3.5% | -3.5% | | | | -3.4% | |
| Effective tax rate | -30.9% | -33.0% | -31.0% | | | | -32.0% | |
| Minority interests | -19 | -9 | 5 | | | | -13 | |
| Net profit att. | 908 | 922 | 1,160 | 77% | 1% | 26% | 926 | -1% |
| NP margins | 9.1% | 7.1% | 7.7% | | | | 7.3% | |
| Sales by segment | | | | | | | | |
| Mass market | 8,841 | 11,128 | 12,779 | 25% | 26% | 15% | 10,987 | 1% |
| Athleisure | 971 | 1,403 | 1,712 | -3% | 44% | 22% | 1,266 | 11% |
| Professional sports | 201 | 400 | 622 | 180% | 99% | 56% | 403 | -1% |
| Total | 10,013 | 12,930 | 15,113 | 23% | 29% | 17% | 12,657 | 2% |



Operating numbers

Figure 5: Sportswear brands sales growth trend

| Mark China Lange 4,00 1, | Operating numbers | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 1Q22 | 2Q22 | 3Q22 | 4Q22E | 1Q23E | 2Q23E | 3Q23E | 4Q23E |
|--|---------------------------|----------|----------|----------|----------|----------|----------|-----------|---------|----------|----------|----------|---------|-------|-------|-------|-------|
| Marian Serial select | | | | | | | | | | | | | | | | | |
| Part | | | | | | | | | | | | | | | | | |
| March 1968 1969 | Anta brand's SSSG | | | | | | | | | | | | | | | | |
| Comparison 1 | Anta brand's retail sales | | -ve LSD | +ve LSD | +ve LSD | 40%-45% | 35%-40% | | | | -ve MSD | +ve MSD | -ve HSD | 10.0% | 10.0% | 16.0% | 23.0% |
| Company Comp | Core brand | 25% | -ve LSD | -ve MSD | -ve MSD | 35%-40% | 35%-40% | +ve HSD | +ve MSD | | | +ve LSD | | | | | |
| Purpose Purp | Kids | | +ve MSD | | | 45%-50% | Over 20% | +ve MSD | | 20%-25% | +ve LSD | +ve HSD | | | | | |
| | Online | +ve MSD | | Over 50% | Over 25% | Over 60% | Over 45% | 25%-30% | 30%-35% | Over 30% | +ve HSD | | | | | | |
| Second Color Col | FILA brand's retail sales | | | 20%-25% | 25%-30% | 75%-80% | 30%-35% | +ve MSD | +ve HSD | +ve MSD | -ve HSD | | teens | 12.0% | 16.0% | 11.0% | 20.0% |
| Fueling Pueling | Classic/ Core brand | | +ve MSD | +ve MSD | +ve MSD | 80% | Over 20% | | | | -ve DD | -ve LSD | teens | | | | |
| Combine 16,000 Owe 80% Owe 90% Owe 9 | Kids | -ve LSD | Over 30% | Over 30% | Over 20% | 100% | Over 40% | teens | teens | | +ve HSD | +ve LSD | | | | | |
| Characterise Ver HSD 25%-30% 50%-55% 55%-60% 115% 120% 120% 50%-40% 30%-35% 40%-45% | Fusion | +ve MSD | Over 70% | Over 50% | Over 50% | 150% | Over 80% | | | Over 20% | -ve MSD | +ve LSD | +ve HSD | | | | |
| Description | Online | 160% | Over 80% | Over 90% | 70%-80% | | Over 40% | 20%-25% | 25%-30% | Over 20% | +ve MSD | Over 65% | | | | | |
| | Other brands | | 25%-30% | 50%-55% | 55%-60% | | 70%-75% | 35%-40% | 30%-35% | 40%-45% | 20%-25% | 40%-45% | teens | | | | |
| Li Ning group's SSSG | Descente | teens | Over 60% | 90% | Over 80% | 150% | 100% | 50% | | 40%-45% | Over 20% | Over 35% | teens | | | | |
| Direct retail Profession | Kolon | | +ve LSD | 20%-25% | | Over 75% | | | teens | | | Over 55% | teens | | | | |
| | Li Ning group's SSSG | n/a | -ve MSD | +ve LSD | | n/a | | | | | | +ve HSD | _ | | | | |
| E - Commerce 1/2 1 | Direct retail | n/a | | -ve MSD | +ve HSD | n/a | | | | | | +ve MSD | | | | | |
| Li Ning group's retail sale ve High teens ve MSD ve MSD ve MSD teens 80% 90% 40% 30% 20% ve HSD ve MSD ve MSD teens 80% 90% 40% 30% 20% ve HSD ve MSD ve | Wholesales | n/a | | -ve MSD | +ve MSD | n/a | | | | | | +ve HSD | | | | | |
| Thing group's retail sale Ver Misco | E- Commerce | | | | | n/a | | | | | +ve LSD | | -ve LSD | | | | |
| Direct retail 30% teens | Li Ning group's retail sa | | -ve MSD | +ve MSD | | | | | | | -ve HSD | | | 2.0% | 13.0% | 5.0% | 31.0% |
| The commerce The | Direct retail | | | Flat | +ve MSD | | | | | | -ve HSD | | | | | | |
| E- Commerce | Wholesales | | -ve HSD | -ve LSD | | | | | | | -ve HSD | | | | | | |
| Xtep's retail sales | E- Commerce | +ve Low- | | | | | | | | | +ve MSD | | | | | | |
| Second S | Xtep's SSSG | | | | | | | | | | | | | | | | , |
| 361 Degree's retail sale -ve 20% - ve Low teens -ve HSD +ve LSD +ve High teens 15%-20% +ve Low teens -ve High teens 15%-20% +ve Low teens -ve High teens -ve Low teens -ve Low to Mid SD -ve Low teens -ve Mid to t | Xtep's retail sales | | -ve LSD | +ve MSD | +ve HSD | | 30%-35% | | 20%-25% | 30%-35% | | 20%-25% | -ve HSD | 18.0% | 7.0% | 8.0% | 23.0% |
| Pou Sheng's SSSG -32.5% -17.8% | 361 Degrees' SSSG | | | | | | | | | | | | | | | | |
| Pou Sheng's sales | 361 Degree's retail sale: | | | -ve HSD | +ve LSD | | 15%-20% | | | | | | Flat | | | | |
| Topsports' retail sales | | | | | | | | | | | | | | | | | |
| Topsports' retail sales | Pou Sheng's sales | -25.1% | 0.3% | -0.3% | 1.0% | 47.8% | -15.0% | -25.1% | | | | -8.5% | | 7.0% | 18.0% | 7.0% | 20.0% |
| Dong Xiang's SSSG | Topsports' retail sales | | | | | | | | 25% | | 20% | -ve LSD | | | | | |
| Dong Xiang's retail sale -ve 25% to 30% -ve Low-teens +ve MSD +ve Low-teens to Mid-teens +ve MSD High-teens -ve MSD High-teens -ve MSD High-teens 30% Direct retail -ve 30%-steens -ve Low-teens Flat +ve MSD 70%-75% -ve MSD High-teens -ve MSD High-teens 30% E- Commerce -ve Low-tye 30%-teens +ve 30%-tye 3 | Dong Xiang's SSSG | | -ve MSD | | +ve MSD | +ve HSD | to High | -ve High- | High- | -ve MSD | to Mid- | | | | | | |
| Direct retail | Dong Xiang's retail sale | | | +ve MSD | | 60%-70% | to Mid- | High- | | | High- | +ve LSD | 20% to | | | | |
| F- Commerce -ve Low- +ve 30%- +ve 20%- 35%_40% | Direct retail | | | Flat | +ve MSD | 70%-75% | | | | | | | | | | | |
| | E- Commerce | -ve Low- | +ve 30%- | | | 35%-40% | | | | | | | | | | | |

Source: Company data, CMBIGM estimates, *Nike's year end is in May (e.g. 4Q18 calendar year = 2Q19 fiscal year = Sep-Nov 2018)



Assumptions

Figure 6: Major assumptions

| Major assumptions | FY21A | FY22A | FY23E | FY24E | FY25E |
|--------------------------------------|--------|--------|--------|--------|--------|
| Sales by segment (RMB mn) | | | | | |
| Shoes | 5,928 | 7,760 | 9,189 | 10,763 | 12,358 |
| Apparels | 3,887 | 4,897 | 5,631 | 6,476 | 7,318 |
| Accessories | 198 | 273 | 292 | 310 | 332 |
| Total | 10,013 | 12,930 | 15,113 | 17,550 | 20,008 |
| Sales by segment growth (%) | | | | | |
| Shoes | 17.5% | 30.9% | 18.4% | 17.1% | 14.8% |
| Apparels | 31.2% | 26.0% | 15.0% | 15.0% | 13.0% |
| Accessories | 22.5% | 38.3% | 7.0% | 6.0% | 7.0% |
| Total | 22.5% | 29.1% | 16.9% | 16.1% | 14.0% |
| Sales by segment (RMB mn) | | | | | |
| Mass market | 8,841 | 11,128 | 12,779 | 14,688 | 16,617 |
| Athleisure | 971 | 1,403 | 1,712 | 2,029 | 2,313 |
| Professional sports | 201 | 400 | 622 | 832 | 1,078 |
| Total | 10,013 | 12,930 | 15,113 | 17,550 | 20,008 |
| Sales by segment growth (YoY) | | | | | |
| Mass market | 24.5% | 25.9% | 14.8% | 14.9% | 13.1% |
| Athleisure | -2.8% | 44.5% | 22.0% | 18.6% | 14.0% |
| Professional sports | 180.3% | 99.0% | 55.6% | 33.8% | 29.6% |
| Total | 22.5% | 29.1% | 16.9% | 16.1% | 14.0% |
| Sales network | | | | | |
| Xtep | 4,722 | 4,493 | 4,628 | 4,767 | 4,910 |
| Xtep kids | 1,179 | 1,520 | 1,672 | 1,789 | 1,878 |
| Oversea stores | 250 | 300 | 300 | 300 | 300 |
| Total | 6,151 | 6,313 | 6,600 | 6,856 | 7,088 |
| GP margins | 41.7% | 40.9% | 41.2% | 41.4% | 41.7% |
| Opex breakdown | | | | | |
| A&P / sales | 10.2% | 11.9% | 11.3% | 11.5% | 11.5% |
| Staff costs/ sales | 11.1% | 11.3% | 11.5% | 11.3% | 11.1% |
| R&D / sales | 2.5% | 2.3% | 2.5% | 2.5% | 2.5% |
| D&A / sales | 1.7% | 1.9% | 1.6% | 1.5% | 1.4% |
| Provisions (write backs) / sales | -0.2% | 0.4% | 0.3% | 0.2% | 0.0% |
| Rental / sales | 0.1% | 0.1% | 0.4% | 0.4% | 0.4% |
| Selling & distribution costs / sales | 18.9% | 20.8% | 20.2% | 20.1% | 19.8% |
| Admin expenses / sales | 11.9% | 11.2% | 11.3% | 11.1% | 10.8% |
| Total | 30.8% | 32.0% | 31.4% | 31.2% | 30.6% |
| OP margins | 13.9% | 11.3% | 12.0% | 12.4% | 13.2% |
| Effective tax rate | 30.9% | 33.0% | 31.0% | 30.0% | 29.0% |
| Net profit att. margins | 9.1% | 7.1% | 7.8% | 8.3% | 9.2% |
| Net profit att. growth (%) | 77.1% | 1.5% | 28.1% | 23.7% | 25.4% |




Valuation

Figure 7: Peers valuation table

| | | | 12m TP | Price | Up/ Down- | Mkt. Cap | Year | P/E | (x) | P/B | (x) | ROE (%) | 3yrs PEG (x) | Yield (%) |
|-----------------|------------------|--------|-----------|---------|--------------|-----------|--------|------|------|------|------|------------|--------------------|--------------|
| Company | Ticker | Rating | (LC) | (LC) | side | (HK\$mn) | End | FY1E | FY2E | FY1E | FY2E | FY1E | FY1E | FY1E |
| H shares Spo | rtswear | | | | | | | | | | | | | |
| Xtep Intl | 1368 HK | BUY | 10.54 | 8.69 | 21% | 22,913 | Dec-22 | 17.3 | 14.0 | 2.2 | 2.0 | 13.5 | 0.7 | 3.5 |
| Anta Sports | 2020 HK | BUY | 126.05 | 111.40 | 13% | 302,298 | Dec-22 | 27.9 | 22.9 | 6.4 | 5.4 | 24.0 | 1.4 | 1.6 |
| Li Ning | 2331 HK | BUY | 66.44 | 60.20 | 10% | 158,689 | Dec-22 | 27.1 | 22.1 | 4.9 | 4.2 | 17.9 | 1.3 | 1.1 |
| 361 Degrees | 1361 HK | NR | n/a | 3.72 | n/a | 7,691 | Dec-22 | 7.5 | 6.6 | 0.7 | 0.7 | 9.9 | 0.4 | 5.6 |
| Topsports | 6110 HK | NR | n/a | 7.09 | n/a | 43,967 | Feb-22 | 18.2 | 14.5 | 3.4 | 3.1 | 21.3 | 3.0 | 4.2 |
| Pou Sheng | 3813 HK | NR | n/a | 0.70 | n/a | 3,728 | Dec-22 | 6.9 | 4.4 | 0.4 | 0.4 | 1.1 | 0.1 | 2.3 |
| China DX | 3818 HK | NR | n/a | 0.34 | n/a | 2,002 | Mar-22 | n/a | 9.9 | 0.2 | 0.2 | (14.0) | 0.0 | 3.4 |
| | | | | | | | Avg. | 17.5 | 13.5 | 2.6 | 2.3 | 10.5 | 1.0 | 3.1 |
| | | | | | | | Med. | 17.7 | 14.0 | 2.2 | 2.0 | 13.5 | 0.7 | 3.4 |
| International S | <u>portswear</u> | | | | | | | | | | | | | |
| Nike Inc | NKE US | NR | n/a | 121.79 | n/a | 1,481,852 | May-22 | 37.9 | 30.5 | 12.9 | 12.4 | 37.3 | 4.9 | 1.1 |
| Adidas | ADS GY | NR | n/a | 141.00 | n/a | 214,930 | Dec-22 | n/a | 33.3 | 5.2 | 4.5 | 9.8 | 0.0 | 8.0 |
| Puma | PUM GY | NR | n/a | 53.62 | n/a | 68,486 | Dec-22 | 22.0 | 16.6 | 3.0 | 2.7 | 14.9 | 1.2 | 1.6 |
| Under Armour | UAA US | NR | n/a | 9.04 | n/a | 29,527 | Mar-23 | 16.6 | 14.5 | 2.0 | 1.8 | n/a | 1.0 | 0.0 |
| Lululemon | LULU US | NR | n/a | 310.22 | n/a | 310,621 | Jan-22 | 31.3 | 27.5 | 11.6 | 9.0 | 41.1 | 1.5 | 0.0 |
| Skechers | SKX US | NR | n/a | 44.79 | n/a | 54,577 | Dec-22 | 15.2 | 12.3 | 1.7 | 1.4 | 10.9 | 0.7 | 0.0 |
| Vf Corp | VFC US | NR | n/a | 21.33 | n/a | 65,052 | Apr-22 | 10.2 | 9.4 | 2.5 | 2.3 | 11.9 | (1.1) | 8.4 |
| Columbia | COLM US | NR | n/a | 87.26 | n/a | 42,574 | Dec-22 | 16.4 | 14.7 | 2.5 | 2.1 | 15.9 | 1.4 | 1.4 |
| Wolverine | WWW US | NR | n/a | 16.84 | n/a | 10,431 | Dec-22 | 11.2 | 8.2 | 2.6 | 2.1 | (40.2) | (0.1) | 2.7 |
| Mizuno Corp | 8022 JP | NR | n/a | 3035.00 | n/a | 4,775 | Mar-22 | 11.3 | 9.9 | 0.7 | 0.7 | 8.1 | (3.6) | 2.0 |
| Asics Corp | 7936 JP | NR | n/a | 3415.00 | n/a | 38,380 | Dec-22 | 25.9 | 22.1 | 3.5 | 3.2 | 12.5 | 1.6 | 1.3 |
| | | | | | | | Avg. | 19.8 | 18.1 | 4.4 | 3.8 | 12.2 | 0.7 | 1.7 |
| | | | | | | | Med. | 16.5 | 14.7 | 2.6 | 2.3 | 12.2 | 1.0 | 1.3 |

Source: Bloomberg, CMBIGM estimates

Figure 8: Forward 12M P/E valuation band



Source: Bloomberg, CMBIGM estimates



Financial Summary

| INCOME STATEMENT | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
|--|---------|---------|---------|---------|----------|----------|
| YE 31 Dec (RMB mn) | | | | | | |
| Revenue | 8,172 | 10,013 | 12,930 | 15,113 | 17,550 | 20,008 |
| Cost of goods sold | (4,973) | (5,835) | (7,639) | (8,888) | (10,276) | (11,663) |
| Gross profit | 3,198 | 4,178 | 5,292 | 6,224 | 7,273 | 8,345 |
| Operating expenses | (2,588) | (3,081) | (4,144) | (4,749) | (5,468) | (6,115) |
| Selling expense | (1,537) | (1,891) | (2,690) | (3,049) | (3,521) | (3,956) |
| Admin expense | (827) | (937) | (1,155) | (1,322) | (1,508) | (1,658) |
| R&D expense | (223) | (252) | (299) | (378) | (439) | (500) |
| Others | Ô | Ô | Ô | , o | , o | Ô |
| Operating profit | 918 | 1,396 | 1,464 | 1,807 | 2,174 | 2,650 |
| Other income | 307 | 299 | 317 | 332 | 369 | 420 |
| Share of (losses)/profits of associates/JV | (17) | (46) | (12) | (6) | 17 | 43 |
| EBITDA | 996 | 1,480 | 1,597 | 1,975 | 2,357 | 2,845 |
| Depreciation | (64) | (71) | (107) | (127) | (131) | (133) |
| Other amortisation | (14) | (13) | (26) | (40) | (52) | (61) |
| Interest income | 4 | 21 | 25 | 39 | 35 | 32 |
| Interest expense | (144) | (85) | (117) | (117) | (117) | (117) |
| Other income/expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax profit | 762 | 1,287 | 1,361 | 1,723 | 2,109 | 2,609 |
| Income tax | (257) | (397) | (449) | (533) | (631) | (754) |
| Minority interest | 8 | 19 | 9 | (5) | (11) | (13) |
| Net profit | 505 | 889 | 912 | 1,190 | 1,478 | 1,855 |
| BALANCE SHEET | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
| YE 31 Dec (RMB mn) | | | | | | |
| Current assets | 9,027 | 10,432 | 11,484 | 12,432 | 13,459 | 14,558 |
| Cash & equivalents | 3,472 | 3,930 | 3,071 | 2,614 | 2,076 | 1,598 |
| Account receivables | 3,236 | 3,528 | 4,556 | 5,325 | 6,184 | 7,050 |
| Inventories | 975 | 1,497 | 1,960 | 2,281 | 2,637 | 2,993 |
| Prepayment | 899 | 1,443 | 1,863 | 2,177 | 2,528 | 2,883 |
| ST bank deposits | 437 | 33 | 33 | 33 | 33 | 33 |
| Other current assets | 8 | 1 | 1 | 1 | 1 | 1 |
| Non-current assets | 3,544 | 4,183 | 4,491 | 4,846 | 5,294 | 5,843 |
| PP&E | 796 | 1,119 | 1,464 | 1,866 | 2,350 | 2,916 |
| Investment in JVs & assos | 218 | 365 | 352 | 346 | 363 | 406 |
| Intangibles | 709 | 671 | 642 | 599 | 545 | 482 |
| Other non-current assets | 1,820 | 2,028 | 2,032 | 2,035 | 2,037 | 2,038 |
| Total assets | 12,572 | 14,615 | 15,975 | 17,278 | 18,753 | 20,400 |
| Current liabilities | 3,334 | 4,053 | 5,092 | 5,829 | 6,649 | 7,471 |
| Short-term borrowings | 642 | 405 | 405 | 405 | 405 | 405 |
| Account payables | 1,479 | 2,352 | 3,079 | 3,583 | 4,143 | 4,702 |
| Tax payable | 86 | 123 | 123 | 123 | 123 | 123 |
| Other current liabilities | 1,127 | 1,173 | 1,485 | 1,718 | 1,979 | 2,242 |
| Non-current liabilities | 1,939 | 2,580 | 2,571 | 2,576 | 2,586 | 2,599 |
| Long-term borrowings | 1,516 | 1,375 | 1,375 | 1,375 | 1,375 | 1,375 |
| Other non-current liabilities | 423 | 1,205 | 1,196 | 1,201 | 1,211 | 1,224 |
| Total liabilities | 5,273 | 6,633 | 7,663 | 8,405 | 9,236 | 10,071 |
| Share capital | 22 | 23 | 23 | 23 | 23 | 23 |
| Retained earnings | 4,671 | 5,020 | 5,185 | 5,658 | 6,242 | 6,975 |
| Other reserves | 2,605 | 2,940 | 3,104 | 3,192 | 3,252 | 3,331 |
| Total shareholders equity | 7,299 | 7,982 | 8,313 | 8,873 | 9,517 | 10,330 |
| Minority interest | 0 | 0 | (9) | (4) | 6 | 19 |
| Total equity and liabilities | 7,299 | 7,982 | 8,322 | 8,877 | 9,511 | 10,310 |



| CASH FLOW | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
|--|----------|----------|----------|----------|----------|----------|
| YE 31 Dec (RMB mn) | | | | | | |
| Operating | | | | | | |
| Profit before taxation | 762 | 1,287 | 1,361 | 1,817 | 2,272 | 2,765 |
| Depreciation & amortization | 78 | 84 | 132 | 168 | 183 | 195 |
| Tax paid | (325) | (329) | (449) | (533) | (631) | (754) |
| Change in working capital | (320) | (447) | (872) | (667) | (746) | (754) |
| Others | 125 | 107 | 12 | (92) | (187) | (209) |
| Net cash from operations | 320 | 701 | 185 | 693 | 892 | 1,242 |
| Investing | | | | | | |
| Capital expenditure | (207) | (414) | (453) | (529) | (614) | (700) |
| Acquisition of subsidiaries/ investments | (4) | (3) | 0 | 0 | 0 | 0 |
| Others | 784 | 89 | 0 | 0 | 0 | 0 |
| Net cash from investing | 573 | (329) | (453) | (529) | (614) | (700) |
| Financing | | | | | | |
| Dividend paid | (279) | (356) | (591) | (633) | (840) | (1,050) |
| Net borrowings | (77) | (312) | 0 | 0 | 0 | 0 |
| Proceeds from share issues | 37 | 0 | 0 | 0 | 0 | 0 |
| Share repurchases | (6) | 0 | 0 | 0 | 0 | 0 |
| Others | (55) | 764 | 0 | 0 | 0 | 0 |
| Net cash from financing | (380) | 96 | (591) | (633) | (840) | (1,050) |
| Net change in cash | | | | | | |
| Cash at the beginning of the year | 2,970 | 3,472 | 3,930 | 3,071 | 2,614 | 2,076 |
| Exchange difference | (11) | (11) | 0 | 0 | 0 | 0 |
| Others | 513 | 469 | (859) | (456) | (539) | (478) |
| Cash at the end of the year | 3,472 | 3,930 | 3,071 | 2,614 | 2,076 | 1,598 |
| GROWTH | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
| YE 31 Dec | | | | | | |
| Revenue | (0.1%) | 22.5% | 29.1% | 16.9% | 16.1% | 14.0% |
| Gross profit | (9.9%) | 30.6% | 26.7% | 17.6% | 16.9% | 14.7% |
| Operating profit | (25.6%) | 52.1% | 4.9% | 23.4% | 20.3% | 21.9% |
| EBITDA | (24.6%) | 48.6% | 7.9% | 23.7% | 19.3% | 20.7% |
| Net profit | (31.0%) | 76.1% | 2.6% | 30.5% | 24.2% | 25.5% |
| PROFITABILITY | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
| YE 31 Dec | | | | | | |
| Gross profit margin | 39.1% | 41.7% | 40.9% | 41.2% | 41.4% | 41.7% |
| Operating margin | 11.2% | 13.9% | 11.3% | 12.0% | 12.4% | 13.2% |
| EBITDA margin | 12.2% | 14.8% | 12.3% | 13.1% | 13.4% | 14.2% |
| Return on equity (ROE) | 7.1% | 11.6% | 11.2% | 13.9% | 16.1% | 18.7% |
| GEARING/LIQUIDITY/ACTIVITIES | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
| YE 31 Dec | | | | | | |
| Net debt to equity (x) | 0.2 | 0.2 | 0.1 | 0.0 | (0.0) | (0.1) |
| Current ratio (x) | 2.7 | 2.6 | 2.3 | 2.1 | 2.0 | 1.9 |
| Receivable turnover days | 144.5 | 128.6 | 128.6 | 128.6 | 128.6 | 128.6 |
| Inventory turnover days | 71.5 | 93.7 | 93.7 | 93.7 | 93.7 | 93.7 |
| Payable turnover days | 108.5 | 147.1 | 147.1 | 147.1 | 147.1 | 147.1 |
| VALUATION | 2020A | 2021A | 2022A | 2023E | 2024E | 2025E |
| YE 31 Dec | | 2.2 | 22.2 | | | |
| P/E | 12.5 | 21.0 | 26.6 | 17.3 | 14.0 | 11.2 |
| P/E (diluted) | 12.5 | 21.0 | 26.6 | 17.3 | 14.0 | 11.2 |
| P/B | 0.9 | 2.4 | 3.0 | 2.3 | 2.1 | 1.9 |
| P/CFPS | 20.0 | 27.2 | 132.5 | 28.9 | 22.5 | 16.1 |
| Div yield (%) | 4.6 | 2.9 | 1.8 | 3.7 | 4.7 | 5.8 |
| EV/Sales | 20,381.7 | 20,707.7 | 22,330.4 | 20,676.8 | 20,960.7 | 21,182.1 |
| | 2.5 | 2.1 | 1.7 | 1.4 | 1.2 | 1.1 |
| EV/EBITDA | 20.5 | 14.0 | 14.0 | 10.5 | 8.9 | 7.4 |

 $Source: Company \ data, CMBIGM \ estimates. \ Note: The \ calculation \ of \ net \ cash \ includes \ financial \ assets.$



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.